文献速递肝病

白细胞介素-22通过重编程受损再生通路改善小鼠慢加急性肝衰竭

Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice.
PubMed 文献 · J Hepatol · 2019-11-29

研究建立联合慢性肝损伤、急性肝损伤和细菌感染的小鼠模型以模拟慢加急性肝衰竭(ACLF),发现肝再生受损源于IL-6/STAT3通路向IFN-γ/STAT1通路偏移。IL-22Fc治疗可逆转该偏移并增强抗菌基因表达,改善小鼠生存,提示其治疗潜力。

要点

  • ACLF小鼠肝再生受损与IL-6/STAT3向IFN-γ/STAT1通路偏移有关
  • IL-22Fc可逆转STAT1/STAT3失衡并增强抗菌基因表达
  • IL-22Fc改善ACLF小鼠生存,提示治疗潜力

核心结论

  • 急性叠加慢性肝损伤或细菌感染通过促再生向抗再生通路偏移导致肝再生受损,IL-22Fc逆转该偏移并减轻细菌感染,可能对ACLF有治疗潜力。

研究设计与样本

  • 研究采用联合慢性四氯化碳注射、双倍剂量四氯化碳急性攻击和腹腔注射细菌的小鼠严重肝损伤模型,并使用ACLF或急性药物性肝损伤患者血清和肝样本。

主要发现

  • 该小鼠模型再现了临床ACLF的急性叠加慢性肝损伤、细菌感染、多器官损伤和高死亡率等部分关键特征。
  • 模型肝再生严重受损,与促再生的IL-6/STAT3通路激活向抗再生的IFN-γ/STAT1通路偏移有关。
  • IL-6/STAT3激活受损源于Kupffer细胞产生IL-6能力不足,STAT1激活增强源于强天然免疫反应及后续IFN-γ产生。
  • 与药物性肝损伤患者相比,ACLF患者IFN-γ水平更高但肝再生更低。
  • IL-22Fc通过逆转STAT1/STAT3通路失衡并经由抗凋亡蛋白BCL2增强多种抗菌基因表达,改善ACLF小鼠生存。

临床怎么用

  • IL-22Fc可能作为ACLF的候选治疗策略,通过重编程受损再生通路并减轻细菌感染发挥作用。

局限性

  • 证据主要来自小鼠模型,临床转化需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Acute-on-chronic liver failure (ACLF) is a clinical syndrome defined by liver failure on pre-existing chronic liver disease. It is often associated with bacterial infection and high short-term mortality. Experimental models that fully reproduce ACLF are lacking, so too are effective pharmacological therapies for this condition. METHODS: To mimic ACLF conditions, we developed a severe liver injury model by combining chronic injury (chronic carbon tetrachloride [CCl4] injection), acute hepatic insult (injection of a double dose of CCl4), and bacterial infection (intraperitoneal injection of bacteria). Serum and liver samples from patients with ACLF or acute drug-induced liver injury (DILI) were used. Liver injury and regeneration were assessed to ascertain the potential benefits of interleukin-22 (IL-22Fc) administration. RESULTS: This severe liver injury model recapitulated some of the key features of clinical ACLF, including acute-on-chronic liver injury, bacterial infection, multi-organ injury, and high mortality. Liver regeneration in this model was severely impaired because of a shift from the activation of the pro-regenerative IL-6/STAT3 pathway to the anti-regenerative IFN-γ/STAT1 pathway. The impaired IL-6/STAT3 activation was due to the inability of Kupffer cells to produce IL-6; whereas the enhanced STAT1 activation was due to a strong innate immune response and subsequent production of IFN-γ. Compared to patients with DILI, patients with ACLF had higher levels of IFN-γ but lower liver regeneration. IL-22Fc treatment improved survival in ACLF mice by reversing the STAT1/STAT3 pathway imbalance and enhancing expression of many antibacterial genes in a manner involving the anti-apoptotic protein BCL2. CONCLUSIONS: Acute-on-chronic liver injury or bacterial infection is associated with impaired liver regeneration due to a shift from a pro-regenerative to an anti-regenerative pathway. IL-22Fc therapy reverses this shift and attenuates bacterial infection, thus IL-22Fc may have therapeutic potential for ACLF treatment. LAY SUMMARY: A mouse model combining chronic liver injury, acute hepatic insult, and bacterial infection recapitulates some of the key features of acute-on-chronic liver failure (ACLF) in patients. Both fibrosis and bacterial infection contribute to the impaired regenerative capacity of the liver in patients with ACLF. Herein, we show that IL-22Fc therapy improves ACLF by reprogramming impaired regenerative pathways and attenuating bacterial infection. Thus, it may have therapeutic potential for patients with ACLF.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Xiang X, Feng D, Hwang S, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol. 2019. PMID: 31786256. doi:10.1016/j.jhep.2019.11.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。